| The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin SB Lee, K Huang, R Palmer, VB Truong, D Herzlinger, KA Kolquist, ... Cell 98 (5), 663-673, 1999 | 364 | 1999 |
| Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry JC Wong, NC Foster, DM Maahs, D Raghinaru, RM Bergenstal, ... Diabetes care 37 (10), 2702-2709, 2014 | 341 | 2014 |
| Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry E Cengiz, D Xing, JC Wong, JI Wolfsdorf, MW Haymond, A Rewers, ... Pediatric diabetes 14 (6), 447-454, 2013 | 287 | 2013 |
| A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience MS Campbell, DA Schatz, V Chen, JC Wong, A Steck, WV Tamborlane, ... Pediatric diabetes 15 (2), 110-117, 2014 | 135 | 2014 |
| Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70 S Maheswaran, C Englert, G Zheng, SB Lee, J Wong, DP Harkin, J Bean, ... Genes & development 12 (8), 1108-1120, 1998 | 122 | 1998 |
| Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis RE Palmer, SB Lee, JC Wong, PA Reynolds, H Zhang, V Truong, ... Cancer cell 2 (6), 497-505, 2002 | 97 | 2002 |
| PedsQL 3.2 diabetes module for children, adolescents, and young adults: reliability and validity in type 1 diabetes JW Varni, AM Delamater, KK Hood, JK Raymond, NT Chang, KA Driscoll, ... Diabetes care 41 (10), 2064-2071, 2018 | 92 | 2018 |
| Prevalence of cardiovascular risk factors in youth with type 1 diabetes and elevated body mass index MJ Redondo, NC Foster, IM Libman, SN Mehta, JM Hathway, KE Bethin, ... Acta diabetologica 53, 271-277, 2016 | 86 | 2016 |
| A low, adaptive dose of gamma-rays reduced the number and altered the spectrum of S1− mutants in human-hamster hybrid A L cells AM Ueno, DB Vannais, DL Gustafson, JC Wong, CA Waldren Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 358 (2 …, 1996 | 78 | 1996 |
| Self-Monitoring of Blood Glucose SK Garg, IB Hirsch, K Ngaosuwan, S Osataphan, MC Carolan-OIah, ... Diabetes Technology & Therapeutics 19 (S1), S-3-S-10, 2017 | 74* | 2017 |
| Diabetes Technology and the Human Factor A Liberman, B Buckingham, KD Barnard, MV Venkat, K Close, ... Diabetes technology & therapeutics 18 (S1), S-101-S-111, 2016 | 72 | 2016 |
| Inequities in diabetic ketoacidosis among patients with type 1 diabetes and COVID-19: data from 52 US clinical centers O Ebekozien, S Agarwal, N Noor, A Albanese-O’Neill, JC Wong, ... The Journal of Clinical Endocrinology & Metabolism 106 (4), 1755-1762, 2021 | 69 | 2021 |
| Evaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry JC Wong, C Boyle, LA DiMeglio, LD Mastrandrea, KL Abel, E Cengiz, ... Journal of diabetes science and technology 11 (2), 224-232, 2017 | 67 | 2017 |
| A minority of patients with type 1 diabetes routinely downloads and retrospectively reviews device data JC Wong, AB Neinstein, M Spindler, S Adi Diabetes technology & therapeutics 17 (8), 555-562, 2015 | 64 | 2015 |
| A case study in open source innovation: developing the Tidepool Platform for interoperability in type 1 diabetes management A Neinstein, J Wong, H Look, B Arbiter, K Quirk, S McCanne, Y Sun, ... Journal of the American Medical Informatics Association 23 (2), 324-332, 2016 | 61 | 2016 |
| Insulin pump use and glycemic control in adolescents with type 1 diabetes: predictors of change in method of insulin delivery across two years JC Wong, LM Dolan, TT Yang, KK Hood Pediatric diabetes 16 (8), 592-599, 2015 | 59 | 2015 |
| Primary γ-sarcoglycanopathy (LGMD 2C): broadening of the mutational spectrum guided by the immunohistochemical profile CG Bönnemann, J Wong, KJ Jones, HGW Lidov, CA Feener, F Shapiro, ... Neuromuscular Disorders 12 (3), 273-280, 2002 | 58 | 2002 |
| Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. JC Wong, SB Lee, MD Bell, PA Reynolds, E Fiore, I Stamenkovic, ... Oncogene 21 (13), 2009-2019, 2002 | 52 | 2002 |
| LGMD 2E in Tunisia is caused by a homozygous missense mutation in β-sarcoglycan exon 3 CG Bönnemann, J Wong, CB Hamida, MB Hamida, F Hentati, LM Kunkel Neuromuscular Disorders 8 (3-4), 193-197, 1998 | 48 | 1998 |
| LGMD 2E in Tunisia is caused by a homozygous missense mutation in β-sarcoglycan exon 3 CG Bönnemann, J Wong, CB Hamida, MB Hamida, F Hentati, LM Kunkel Neuromuscular Disorders 8 (3-4), 193-197, 1998 | 45 | 1998 |
